Stockreport

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Immunovant, Inc.  (IMVT) 
PDF Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves’ disease (GD) and difficult-to-tr [Read more]